Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States

CONCLUSION: Mosunetuzumab is estimated to be cost-effective compared with approved regimens except R-Len for the treatment of adults with R/R FL.PMID:38712895 | DOI:10.1080/13696998.2024.2352820

Source: Journal of Medical Economics - May 7, 2024 Category: Health Management Authors: Matthew Matasar Javier Sanchez Alvarez H élène Parisé Eric Zuk Danilo Di Maio Sheila Shapouri Eunice Kim Shih-Wen Lin Source Type: research